Drug intelligence / Profile preview

YHD1023

Development stage: Phase 2
Lead developer: Yuhan
Modality: Small Molecules
Administration: Oral

Overview

**YHD1023** is an orally administered Yuhan investigational small-molecule therapy for erectile dysfunction. It was evaluated in a randomized, double-blind, placebo- and active-controlled Phase II study in South Korea, with oral 5 g and 10 g dose groups. Public drug-development databases characterize YHD1023 as a phosphodiesterase type 5A inhibitor with nitric oxide synthase-stimulating activity, a dual mechanism intended to enhance nitric oxide-cGMP signaling and penile smooth-muscle relaxation. The registered Phase II study was completed, but YHD1023 has not been identified as an approved product and no subsequent active development program has been publicly confirmed.

Other names: YHD-1023YHD1023YHD 1023

Targets

PDE5 (Phosphodiesterase 5A)NOS1 (nNOS)

Beyond the preview

Go deeper on YHD1023.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on YHD1023.

Explore the full profile